{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:25:42Z","timestamp":1790634342633,"version":"4.1.0"},"reference-count":61,"publisher":"The Editorial Committee of Annals of Vascular Diseases","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Vascular Diseases","Ann Vasc Dis","AVD"],"published-print":{"date-parts":[[2020,6,25]]},"DOI":"10.3400\/avd.ra.20-00035","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T22:10:17Z","timestamp":1588198217000},"page":"109-115","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic Angiogenesis Using HGF Plasmid"],"prefix":"10.3400","volume":"13","author":[{"given":"Fumihiro","family":"Sanada","sequence":"first","affiliation":[{"name":"Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Taniyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[{"name":"Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1983","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Christov C, Chretien F, Abou-Khalil R, et al. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol Biol Cell 2007; <b>18<\/b>: 1397-409.","DOI":"10.1091\/mbc.e06-08-0693"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gurtner GC, Werner S, Barrandon Y, et al. Wound repair and regeneration. Nature 2008; <b>453<\/b>: 314-21.","DOI":"10.1038\/nature07039"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Bache RJ, Schwartz JS. Myocardial blood flow during exercise after gradual coronary occlusion in the dog. Am J Physiol 1983; <b>245<\/b>: H131-8.","DOI":"10.1152\/ajpheart.1983.245.1.H131"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999; <b>103<\/b>: 1231-6.","DOI":"10.1172\/JCI6889"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; <b>93<\/b>: 662-70.","DOI":"10.1172\/JCI117018"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sieveking DP, Ng MK. Cell therapies for therapeutic angiogenesis: back to the bench. Vasc Med 2009; <b>14<\/b>: 153-66.","DOI":"10.1177\/1358863X08098698"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Sanada F, Taniyama Y, Iekushi K, et al. Negative action of hepatocyte growth factor\/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res 2009; <b>105<\/b>: 667-75, 13, 675.","DOI":"10.1161\/CIRCRESAHA.109.202713"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sanada F, Taniyama Y, Azuma J, et al. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension 2009; <b>53<\/b>: 77-82.","DOI":"10.1161\/HYPERTENSIONAHA.108.120725"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Shimizu K, Taniyama Y, Sanada F, et al. Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation. Arterioscler Thromb Vasc Biol 2012; <b>32<\/b>: 2687-93.","DOI":"10.1161\/ATVBAHA.112.300041"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Muratsu J, Iwabayashi M, Sanada F, et al. Hepatocyte growth factor prevented high-fat diet-induced obesity and improved insulin resistance in mice. Sci Rep 2017; <b>7<\/b>: 130.","DOI":"10.1038\/s41598-017-00199-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kusunoki H, Taniyama Y, Rakugi H, et al. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptor\u03b3-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. J Am Heart Assoc 2013; <b>2<\/b>: e000103.","DOI":"10.1161\/JAHA.113.000103"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Okayama K, Azuma J, Dosaka N, et al. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 2012; <b>59<\/b>: 958-65.","DOI":"10.1161\/HYPERTENSIONAHA.111.183905"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kusunoki H, Taniyama Y, Azuma J, et al. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-\u03b3\/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension 2012; <b>59<\/b>: 308-16.","DOI":"10.1161\/HYPERTENSIONAHA.111.176263"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kim I, Moon SO, Hoon Kim S, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; <b>276<\/b>: 7614-20.","DOI":"10.1074\/jbc.M009705200"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kaga T, Kawano H, Sakaguchi M, et al. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol 2012; <b>57<\/b>: 3-9.","DOI":"10.1016\/j.vph.2012.02.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Zhao Q, Egashira K, Hiasa K, et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol 2004; <b>24<\/b>: 2284-9.","DOI":"10.1161\/01.ATV.0000147161.42956.80"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mei L, He Y, Wang H, et al. Human hepatocyte growth factor inhibits early neointima formation in rabbit abdominal aortae following ultrasound-guided balloon injury. Mol Med Rep 2017; <b>16<\/b>: 5203-10.","DOI":"10.3892\/mmr.2017.7229"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Min JK, Lee YM, Kim JH, et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 2005; <b>96<\/b>: 300-7.","DOI":"10.1161\/01.RES.0000155330.07887.EE"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; <b>116<\/b>: 1793-801.","DOI":"10.1172\/JCI29069"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Andreozzi F, Laratta E, Procopio C, et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 2007; <b>27<\/b>: 2372-83.","DOI":"10.1128\/MCB.01340-06"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lauterbach MA, Wunderlich FT. Macrophage function in obesity-induced inflammation and insulin resistance. Pflugers Arch 2017; <b>469<\/b>: 385-96.","DOI":"10.1007\/s00424-017-1955-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kusunoki H, Taniyama Y, Otsu R, et al. Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes. Hypertens Res 2014; <b>37<\/b>: 500-6.","DOI":"10.1038\/hr.2014.41"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ara\u00fajo TG, Oliveira AG, Carvalho BM, et al. Hepatocyte growth factor plays a key role in insulin resistance-associated compensatory mechanisms. Endocrinology 2012; <b>153<\/b>: 5760-9.","DOI":"10.1210\/en.2012-1496"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Perdomo G, Martinez-Brocca MA, Bhatt BA, et al. Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells. J Biol Chem 2008; <b>283<\/b>: 13700-6.","DOI":"10.1074\/jbc.M707551200"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sanchez-Encinales V, Cozar-Castellano I, Garcia-Oca\u00f1a A, et al. Targeted delivery of HGF to the skeletal muscle improves glucose homeostasis in diet-induced obese mice. J Physiol Biochem 2015; <b>71<\/b>: 795-805.","DOI":"10.1007\/s13105-015-0444-6"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Flaquer M, Franquesa M, Vidal A, et al. Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db\/db mice as a model of diabetes. Diabetologia 2012; <b>55<\/b>: 2059-68.","DOI":"10.1007\/s00125-012-2535-z"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Sanada F, Kanbara Y, Taniyama Y, et al. Induction of angiogenesis by a type iii phosphodiesterase inhibitor, cilostazol, through activation of peroxisome proliferator-activated receptor-\u03b3 and camp pathways in vascular cells. Arterioscler Thromb Vasc Biol 2016; <b>36<\/b>: 545-52.","DOI":"10.1161\/ATVBAHA.115.307011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009; <b>89<\/b>: 47-58.","DOI":"10.1038\/labinvest.2008.104"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; <b>109<\/b>: 227-41.","DOI":"10.1042\/CS20040370"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; <b>93<\/b>: 662-70.","DOI":"10.1172\/JCI117018"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Walder CE, Errett CJ, Bunting S, et al. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc Pharmacol 1996; <b>27<\/b>: 91-8.","DOI":"10.1097\/00005344-199601000-00015"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 2000; <b>70<\/b>: 829-34.","DOI":"10.1016\/S0003-4975(00)01633-7"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; <b>18<\/b>: 3964-72.","DOI":"10.1093\/emboj\/18.14.3964"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; <b>97<\/b>: 1114-23.","DOI":"10.1161\/01.CIR.97.12.1114"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) M\u00e4kinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; <b>6<\/b>: 127-33.","DOI":"10.1006\/mthe.2002.0638"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Rajagopalan S, Mohler E 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J 2003; <b>145<\/b>: 1114-8.","DOI":"10.1016\/S0002-8703(03)00102-9"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; <b>17<\/b>: 683-91.","DOI":"10.1089\/hum.2006.17.683"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Monaghan-Benson E, Burridge K. The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species. J Biol Chem 2009; <b>284<\/b>: 25602-11.","DOI":"10.1074\/jbc.M109.009894"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Ehrbar M, Djonov VG, Schnell C, et al. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res 2004; <b>94<\/b>: 1124-32.","DOI":"10.1161\/01.RES.0000126411.29641.08"},{"key":"40","unstructured":"40) Deroanne CF, Hajitou A, Calberg-Bacq CM, et al.  Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997; <b>57<\/b>: 5590-7."},{"key":"41","unstructured":"41) Flynn A, O\u2019Brien T. Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs 2008; <b>11<\/b>: 283-93."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Chen PY, Qin L, Tellides G, et al. Fibroblast growth factor receptor 1 is a key inhibitor of TGF\u03b2 signaling in the endothelium. Sci Signal 2014; <b>7<\/b>: ra90.","DOI":"10.1126\/scisignal.2005504"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Oladipupo SS, Smith C, Santeford A, et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci USA 2014; <b>111<\/b>: 13379-84.","DOI":"10.1073\/pnas.1324235111"},{"key":"44","unstructured":"44) Gon\u00e7alves LM. Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Rev Port Cardiol 1998; <b>17<\/b> <b>Suppl 2<\/b>: II11-20."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; <b>35<\/b>: 930-6.","DOI":"10.1067\/mva.2002.123677"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; <b>16<\/b>: 972-8.","DOI":"10.1038\/mt.2008.33"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; <b>377<\/b>: 1929-37.","DOI":"10.1016\/S0140-6736(11)60394-2"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Wojakowski W, Tendera M, Micha\u0142owska A, et al. Mobilization of CD34\/CXCR4+, CD34\/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004; <b>110<\/b>: 3213-20.","DOI":"10.1161\/01.CIR.0000147609.39780.02"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Tokunou M, Niki T, Eguchi K, et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; <b>158<\/b>: 1451-63.","DOI":"10.1016\/S0002-9440(10)64096-5"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; <b>118<\/b>: 58-65.","DOI":"10.1161\/CIRCULATIONAHA.107.727347"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010; <b>17<\/b>: 1152-61.","DOI":"10.1038\/gt.2010.51"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; <b>44<\/b>: 203-9.","DOI":"10.1161\/01.HYP.0000136394.08900.ed"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Makino H, Aoki M, Hashiya N, et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 2012; <b>32<\/b>: 2503-9.","DOI":"10.1161\/ATVBAHA.111.244632"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Ohtani K, Egashira K, Hiasa K, et al. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation 2004; <b>110<\/b>: 2444-52.","DOI":"10.1161\/01.CIR.0000145123.85083.66"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor\/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998; <b>97<\/b>: 381-90.","DOI":"10.1161\/01.CIR.97.4.381"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001; <b>158<\/b>: 1111-20.","DOI":"10.1016\/S0002-9440(10)64058-8"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Okayama K, Azuma J, Dosaka N, et al. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 2012; <b>59<\/b>: 958-65.","DOI":"10.1161\/HYPERTENSIONAHA.111.183905"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Iekushi K, Taniyama Y, Kusunoki H, et al. Hepatocyte growth factor attenuates transforming growth factor-\u03b2-angiotensin II crosstalk through inhibition of the PTEN\/Akt pathway. Hypertension 2011; <b>58<\/b>: 190-6.","DOI":"10.1161\/HYPERTENSIONAHA.111.173013"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Iekushi K, Taniyama Y, Azuma J, et al. Hepatocyte growth factor attenuates renal fibrosis through TGF-\u03b21 suppression by apoptosis of myofibroblasts. J Hypertens 2010; <b>28<\/b>: 2454-61.","DOI":"10.1097\/HJH.0b013e32833e4149"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 2006; <b>13<\/b>: 1206-13.","DOI":"10.1038\/sj.gt.3302740"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Criqui MH. Peripheral arterial disease\u2013epidemiological aspects. Vasc Med 2001; <b>6<\/b> <b>Suppl<\/b>: 3-7.","DOI":"10.1177\/1358836X0100600i102"}],"container-title":["Annals of Vascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/avd\/13\/2\/13_ra.20-00035\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T04:17:21Z","timestamp":1593231441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/avd\/13\/2\/13_ra.20-00035\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3400\/avd.ra.20-00035","relation":{},"ISSN":["1881-641X","1881-6428"],"issn-type":[{"value":"1881-641X","type":"print"},{"value":"1881-6428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}